To print: Select File and then Print from your browser's menu

Title: Once Weekly Risedronate Increases Bone Mineral Density In Osteoporosis And Osteopenia Patients

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12113633&dopt=Abstract

Endocr Pract 2002; 8(3):202-207 "Response of bone mineral density to once-weekly administration of risedronate"
07/22/2002 05:40:50 PM
By David Ball

Bone mineral density (BMD) can be increased in patients with osteoporosis or osteopenia with risedronate, 30 mg once weekly, alone or with other antiresorptive agents. In a study of 70 patients, few adverse events were associated with this therapy, says Dr. M. S. Gordon at Harvard Medical School, Boston and University School of Medicine, Pennsylvania, United States. Subjects with osteoporosis or osteopenia were given a once-weekly 30-mg regimen of risedronate before breakfast. Supplemental vitamin D and 1,500 mg of calcium daily were also given to all patients and those receiving other antiresorptive agents were included in the study. Dual-energy x-ray absorptiometry (DEXA) assessed BMD at baseline and at one year. In all subjects, after a mean of 11.6 months, mean BMD increased at the lumbar spine by 5.7 percent, and at total hip by 2.9 percent. In 23 treated with risedronate alone, BMD increased by 4.8 percent at lumbar spine and 2.2 percent at total hip. Among 21 patients receiving risedronate and other antiresorptive agents the increase was by 6.7 percent and 3.6 percent, respectively. A statistically significant negative correlation was found between baseline T-score and BMD increment at the lumbar spine and femoral neck in analysing this relationship by linear regression. According to Dr Gordon this indicated an enhanced response to treatment in those with lower baseline T-scores. In three patients, adverse events (two cases of dyspepsia and one of urticaria)were possibly associated with risedronate treatment. Follow-up dual x-ray absorptiometry scans in 44 patients showed that 12 subjects who had not previously tolerated alendronate (10 mg daily) had no difficulty tolerating once-weekly risedronate therapy.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12113633&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.